The Bennett Pharma Team

  • Dr. Megan Adelman

    Pharmacist in Charge

  • Jim Mulvahill

    CEO

  • Katie Burgess

    President

  • Dr. Michael Smilanich

    Medical Director

  • Dr. Alyssa Real

    Director of Quality

  • Alissia Satisfield

    Production and Fulfillment Manager

The Bennett Pharma Team

  • Dr. Megan Adelman, Pharmacist-in-charge

    Dr. Megan Adelman serves as Pharmacist-in-Charge for Bennett Pharmaceuticals of America, bringing professional pharmacy leadership and oversight to the company’s 503B outsourcing operations. In her role, she supports pharmacy practice standards, medication quality processes, regulatory awareness, and responsible operational execution within a cGMP-focused environment. Her clinical pharmacy background and attention to quality help support Bennett’s commitment to serving healthcare professionals with reliable, appropriately managed pharmaceutical products.

  • Jim Mulvahill, CEO

    Jim Mulvahill is a healthcare and pharmaceutical executive with direct CEO-level experience building and operating a federally registered 503B outsourcing facility. As CEO and co-founder of Bennett Pharmaceuticals of America, he has led work across cGMP operations, licensure strategy, sterile production readiness, quality systems, product commercialization, investor relations, and healthcare market development. His experience is especially relevant for organizations evaluating 503B startups, acquisitions, facility operations, compliance strategy, product development, and commercialization of office-administered pharmaceutical products. Jim brings a practical operator’s perspective grounded in the real-world challenges of building, scaling, and positioning a specialized pharmaceutical manufacturing business.

  • Katie Burgess, President

    Kathryn Burgess is a business and marketing leader with experience in healthcare commercialization, customer education, sales strategy, brand development, and organizational growth. As President of Bennett Pharmaceuticals of America, she helps guide the company’s customer-facing strategy for a federally registered 503B outsourcing facility serving healthcare professionals. Her work includes market development, provider education, customer communications, strategic partnerships, evaluation program support, investor communications, and compliance-conscious messaging for pharmaceutical products used in professional healthcare settings. With a background in journalism and mass communications, along with advanced training in educational technology, Kathryn brings a strong ability to translate complex product, regulatory, and workflow concepts into clear, practical information for dentists, physicians, hospitals, and healthcare organizations. She has played an important role in developing Bennett’s launch and market positioning of products including Orlicaine and MaxMist, and helping healthcare providers understand how Bennett’s products may fit within appropriate clinical and operational workflows.

  • Dr. Michael Smilanich, Medical Director

    Dr. Michael Smilanich serves as Medical Director for Bennett Pharmaceuticals of America, bringing decades of clinical experience in dentistry and patient care to the company’s leadership team. With more than 40 years of experience as a restorative dentist, Dr. Smilanich provides clinical perspective on product use, provider workflows, patient comfort, and practical implementation in professional healthcare settings. His background helps support Bennett’s commitment to developing products and education that are relevant, responsible, and aligned with the needs of dentists, physicians, and the patients they serve.

  • Dr. Alyssa Real, Director of Quality

    Dr. Alyssa Real serves as Director of Quality for Bennett Pharmaceuticals of America, bringing extensive pharmacy, sterile compounding, and quality credentials to the leadership team. She is a PharmD, MS RAQA, Board Certified Sterile Compounding Pharmacist, and ASQ Certified Quality Auditor, with registered pharmacist licenses across multiple states including Minnesota, Wisconsin, Illinois, Texas, Indiana, Montana, Pennsylvania, Nebraska, Iowa, Michigan, Mississippi, and South Carolina. Her additional training includes ASHP sterile compounding and pharmacy leadership certificates, medication therapy management, immunization delivery, pain management, and managed care pharmacy. Dr. Real’s broad licensure, quality auditing background, and sterile compounding expertise help support Bennett’s quality systems, operational oversight, and commitment to serving healthcare professionals with well-managed pharmaceutical solutions.

  • Alissia Satisfield, Production and Fulfillment Manager

    Alissia Satisfield serves as Production and Fulfillment Manager and Customer Care Coordinator for Bennett Pharmaceuticals of America. In her role, she supports day-to-day production coordination, order fulfillment, customer communication, and operational follow-through within Bennett’s 503B outsourcing environment. Her work helps ensure healthcare professionals receive responsive support, organized fulfillment, and clear communication from the Bennett team. Alissia’s attention to detail, customer-focused approach, and operational reliability help support Bennett’s commitment to consistent service and well-managed pharmaceutical solutions.

we are:

Bennett Pharmaceuticals of America is a pharmaceutical manufacturer and wholesaler committed to improving patient access to high quality medicines. We aim to establish a new, superior standard for patient comfort and care by enhancing clinicians' access to our high-quality, minimally invasive, injection-free, and non-opioid medications.

We are an FDA-registered 503B manufacturing facility producing sterile and non-sterile pharmaceutical products. As a registered 503B pharmaceutical manufacturer and wholesaler, Bennett serves doctors, hospitals, veterinarians and dentists.

This site is intended only for medical professionals.

What sets us apart:

  • Bennett Pharma is only one of seventy-four 503B Manufacturing Facilities in the United States. The goal of the law is to increase patient safety. A 503B outsourcing facility is different than a traditional compound pharmacy because it is registered with the FDA, it is inspected by the FDA, it manufactures sterile drugs, it follows cGMP (current good manufacturing practices) and all products undergo rigorous testing.

    As a 503B we can:

    • compound any products on the bulk substance list

    • produce any drugs on the drug shortage list

    • sell for office stock (rather than single, prescriptions)

    • provide needed medications to the medical, dental, and veterinary industries.

  • Bennett Pharmaceuticals is committed to significantly enhancing patient comfort through our superior proprietary topical anesthetics. We aim to set a new standard of patient care in both the medical and dental industries. By forging strategic partnerships, we will revolutionize pain management and transform patient experiences across the healthcare landscape.

  • Orlicaine and STAT have formulation and method patent protection that will provide 20 years exclusivity from the date of filing of the provisional patent application. As a 503B outsourcing facility Bennett manufactures Orlicaine and STAT as products and sells directly to doctors, clinics, hospitals, dentists, GPOs and DSOs (dental service organizations) at the wholesale level.

  • Bennett Pharma is committed to producing the highest quality compounded pharmaceuticals. All batches are produced according to cGMP and tested prior to release.

  • Establish a new, superior standard for patient comfort and care by enhancing clinicians' access to our high-quality, minimally invasive, injection-free, and non-opioid medications produced in our 503B Pharmacy according to cGMP.

Contact us:

Phone: +1-612-356-2224
Email: info@bennett-pharma.com

596 Outpost Circle, Suite B, Hudson, WI 54016